Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.4959215Ifosfamide-mesna lyophilizate and process for its preparation
US 25.09.1990
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No 07325883 Applicant Asta Pharma AG Inventor Sauerbier Dieter

An ifosfamide-mesna lyophilizate consists substantially of ifosfamide, 0.1-1.0 parts by weight of mesna and 0.1 to 17 parts by weight of hexitol. The product is obtained by freeze drying an aqueous or aqueous-ethanolic solution of ifosfamide and mesna.

2.1020210048608다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
KR 03.05.2021
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 1020217012517 Applicant 브라운, 데니스, 엠. Inventor 바차, 제프리
디안히드로갈락티톨의 사용은 다형교모세포종 및 수모세포종의 치료에 있어서 새로운 치료학적 방법론을 제공한다. 디안히드로갈락티톨은 N 메틸화를 생성하는 DNA에 대해 알킬화제로서 작용한다. 디안히드로갈락티톨은 암 줄기세포의 성장을 억제하는데 효과적이고 테모졸로마이드로는 난치성인 종양에 대해 활성적이며; 이 약물은 MGMT 복구 메카니즘과는 독립적으로 작용한다. 7
3.104427984Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
CN 18.03.2015
Int.Class A61K 31/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
Appl.No 201380015319.5 Applicant BROWN DENNIS Inventor BACHA JEFFREY
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
4.1020160065776재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR 09.06.2016
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 1020157037286 Applicant 델 마 파마슈티컬스 인코포레이티드 Inventor 브라운, 데니스, 엠.
재발성 신경교종 및 진행성 2차 뇌종양과 같은 악성 종양의 치료에 적합한 방법 및 조성물이 개시된다. 이들 방법은 디안히드로갈락티톨, 디안히드로갈락티톨의 유도체 또는 유사체, 디아세틸디안히드로갈락티톨, 또는 디아세틸디안히드로갈락티톨의 유도체 또는 유사체와 같은 헥시톨 유도체를 사용한다. 조성물은 이러한 헥시톨 유도체를 포함할 수 있다.
5.107231794Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme
CN 03.10.2017
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 201580071196.6 Applicant DEL MAR PHARMACEUTICALS Inventor BACHA JEFFREY A
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
6.105579044双脱水半乳糖醇及其类似物与衍生物用于治疗复发性恶性神经胶瘤或进行性继发脑瘤的用途
CN 11.05.2016
Int.Class A61K 31/7024
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7024Esters of saccharides
Appl.No 201480042784.2 Applicant 德玛医药 Inventor D·M·布朗

所揭露为适用于治疗恶性肿瘤诸如复发性神经胶瘤及进行性继发脑瘤的方法及组合物。这些方法采用己糖醇衍生物如双脱水半乳糖醇、双脱水半乳糖醇的衍生物或类似物、二乙酰双脱水半乳糖醇或二乙酰双脱水半乳糖醇的衍生物或类似物。该组合物可包含该等己糖醇衍生物。

7.115778934Use of substituted hexitols for treatment of malignancies
CN 14.03.2023
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 202211320632.7 Applicant DERMA CO., LTD. Inventor BASHA JEFFREY
The present invention relates to the use of substituted hexitols for the treatment of malignancies. The use of dianhydrogalactitol provides a novel way of treatment to treat glioblastoma multiforme and neuroblastoma. The dianhydrogalactitol is used as an alkylating agent to act on DNA (deoxyribonucleic acid) to cause N7 methylation. The dianhydrogalactitol is effective in inhibiting the growth of cancer stem cells and has the activity of resisting temozolomide-resistant tumors; the drug effect is irrelevant to MGMT repair mechanism.
8.110711188Use of substituted hexitols to treat malignant tumors
CN 21.01.2020
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 201910649595.6 Applicant DELMAR PHARMACEUTICALS INC. Inventor BACHA JEFFREY
Use of substituted hexitols to treat malignant tumors. The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
9.115813902Use of substituted hexitols for treatment of malignancies
CN 21.03.2023
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 202211319179.8 Applicant DERMA CO., LTD. Inventor BASHA JEFFREY
The present invention relates to the use of substituted hexitols for the treatment of malignancies. The use of dianhydrogalactitol provides a novel way of treatment to treat glioblastoma multiforme and neuroblastoma. The dianhydrogalactitol is used as an alkylating agent to act on DNA (deoxyribonucleic acid) to cause N7 methylation. The dianhydrogalactitol is effective in inhibiting the growth of cancer stem cells and has the activity of resisting temozolomide-resistant tumors; the drug effect is irrelevant to MGMT repair mechanism.
10.0051467HEXITOL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP 12.05.1982
Int.Class A61K 31/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
Appl.No 81305161 Applicant CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. Inventor ELEKES, ILONA
Hexitols of the general formula (wherein the hexitol skeleton corresponds to dulcitol, mannitol or iditol, R@ represents a halogen atom, R<3> represents a hydroxy group, or R<2> and R<3> together form an oxygen atom; R represents a free carboxy containing saturated or unsaturated alkylcarbonyl group with 4 to 10 carbon atoms, a free carboxy containing arylcarbonyl group with 8 to 12 carbon atoms or a free carboxy containing satiurated or unsaturated aralkylcarbonyl group with 9 to 11 carbon atoms) and Rs@ represents a hydrogen atom, a free carboxy containing saturated or unsaturated alkylcarbonyl group with 4 to 10 carbon atoms, a saturated or unsaturated C2-10 alkylcarbonyl group, an alkoxycarbonyl containing saturated or unsaturated alkylcarbonyl group with 4 to 10 carbon atoms, a saturated or unsaturated C8-10 aralkylcarbonyl group, a free carboxy containing arylcarbonyl group with 8 to 12 carbon atoms or a free carboxy containing saturated or unsaturated aralkylcarbonyl group with 9 to 11 carbon atoms) and salts thereof possess tumour inhibiting activity. The hexitols of the present invention are prepared by hydrogenation of a corresponding benzyloxycarbonyl containing 1,2-5,6-dianhydrohexitol, reaction of 1,2-5,6-dianhydrohexitol with a dicarboxylic acid anhydride and halogenation of a corresponding 1,2-5,6-dianhydrohexitol.